UK markets open in 3 hours 39 minutes
NIKKEI 225
38,303.39 -531.71 (-1.37%) HANG SENG
18,537.83 +58.46 (+0.32%) CRUDE OIL
78.05 -0.33 (-0.42%) GOLD FUTURES
2,323.60 -0.60 (-0.03%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,182.37 -779.93 (-1.53%)
Daiichi Sankyo Company, Limited (DSNKY)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:58PM EDT
| Previous close | 36.17 |
| Open | 34.35 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 34.26 - 35.34 |
| 52-week range | 23.72 - 37.57 |
| Volume | |
| Avg. volume | 180,214 |
| Market cap | 65.889B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 50.53 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.24 (0.68%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | N/A |
- Business Wire
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
- Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors
- Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
© 2024 Yahoo. All rights reserved.